GlobeNewswire: AnGes MG, Inc. Contains the last 10 of 6 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T14:07:12ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/04/05/1797459/0/en/AnGes-Obtains-Conditional-Approval-in-Japan-for-HGF-Gene-Therapy-to-Treat-Critical-Limb-Ischemia.html?f=22&fvtc=4&fvtv=17641AnGes Obtains Conditional Approval in Japan for HGF Gene Therapy to Treat Critical Limb Ischemia2019-04-05T02:00:52Z<![CDATA[TOKYO, April 05, 2019 (GLOBE NEWSWIRE) -- AnGes, Inc., a biopharmaceutical company focused on developing innovative gene-based medicines for treating serious diseases, announced today that they have obtained conditional approval (“Approval with Conditions and Time Limit”) from the Japanese Ministry of Health, Labour and Welfare (MHLW) for HGF plasmid to treat patients with critical limb ischemia (CLI).]]>https://www.globenewswire.com/news-release/2018/07/31/1544468/0/en/Vasomune-Therapeutics-and-AnGes-Inc-enter-into-a-Multi-Million-Dollar-Global-Co-Development-Agreement-to-Advance-an-Innovative-Platform-Targeting-Vascular-Leakage.html?f=22&fvtc=4&fvtv=17641Vasomune Therapeutics and AnGes, Inc. enter into a Multi-Million Dollar Global Co-Development Agreement to Advance an Innovative Platform Targeting Vascular Leakage2018-07-31T11:00:00Z<![CDATA[TOKYO and TORONTO, July 31, 2018 (GLOBE NEWSWIRE) -- Vasomune Therapeutics (“Vasomune”), a Toronto-based spin-out from Sunnybrook Research Institute and MaRS Innovation, and AnGes, Inc. (Tokyo, TYO:4563), a Japan-based biotechnology company focused on developing biotherapeutics, announce the signing of an innovative global Co-Development Agreement for the development and commercialization of therapeutics treating diseases associated with blood vessel dysfunction and destabilization.]]>https://www.globenewswire.com/news-release/2018/02/28/1396561/0/en/AnGes-Announces-First-Patient-Treated-with-NF-kappa-B-Decoy-in-Phase-Ib-Study-to-Treat-Discogenic-Low-Back-Pain.html?f=22&fvtc=4&fvtv=17641AnGes Announces First Patient Treated with NF-kappa B Decoy in Phase Ib Study to Treat Discogenic Low Back Pain2018-02-28T00:31:42Z<![CDATA[TOKYO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- AnGes, Inc., a biopharmaceutical company focused on developing innovative gene-based medicines for serious diseases, announced today the treatment of the first patient with NF-kappa B decoy oligo DNA (NF-kB Decoy) in the US phase Ib clinical trial in patients with chronic discogenic low back pain (DLBP).]]>https://www.globenewswire.com/news-release/2018/01/23/1298857/0/en/AnGes-Submits-Application-for-Marketing-Approval-to-PMDA-for-HGF-gene-therapy-for-Critical-Limb-Ischemia.html?f=22&fvtc=4&fvtv=17641AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia2018-01-23T03:11:18Z<![CDATA[TOKYO, Jan. 23, 2018 (GLOBE NEWSWIRE) -- AnGes, Inc., a biopharmaceutical company focused on developing innovative gene-based medicines for serious diseases, announced today the submission of an application for marketing approval to the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan for HGF plasmid, an investigational gene therapy for the treatment of critical limb ischemia (CLI), the most severe condition of peripheral arterial disease.]]>https://www.globenewswire.com/news-release/2014/10/06/670702/10101290/en/AnGes-Starts-Global-Phase-III-Clinical-Trials-of-Collategene-R-for-Critical-Limb-Ischemia.html?f=22&fvtc=4&fvtv=17641AnGes Starts Global Phase III Clinical Trials of Collategene(R) for Critical Limb Ischemia2014-10-06T00:20:27Z<![CDATA[
TOKYO, Oct. 6, 2014 (GLOBE NEWSWIRE) -- AnGes MG, Inc. ("AnGes") announces that it has commenced the global phase III clinical trials of Collategene]]>https://www.globenewswire.com/news-release/2012/10/24/499187/10009566/en/AnGes-Enters-Into-the-Definitive-Agreement-With-Mitsubishi-Tanabe-Pharma-for-Exclusive-Marketing-Rights-of-Collategene-R-in-the-United-States.html?f=22&fvtc=4&fvtv=17641AnGes Enters Into the Definitive Agreement With Mitsubishi Tanabe Pharma for Exclusive Marketing Rights of Collategene(R) in the United States2012-10-24T03:00:00Z<![CDATA[
TOKYO, Oct. 24, 2012 (GLOBE NEWSWIRE) -- AnGes MG Inc. ("AnGes") announced today that the company has entered into a definitive agreement with Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka, President & CEO, Michihiro Tsuchiya, "MTPC") for the exclusive marketing rights of Collategene]]>